Physician profile
Simone Jensen
NPI 1174973325
$5,804.86
in general payments reported to CMS, 2019-2025
26 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $282 · 2023: $502 · 2024: $2,471 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,784.31 |
| Education | $295.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.38 | 2023-2025 | |
| Allergan, INC. | $647.98 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $599.43 | 2024-2025 | Dupixent |
| Ucb, INC. | $420.74 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $380.96 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Janssen Biotech, INC. | $363.20 | 2024-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $241.48 | 2024-2025 | Siliq, Cabtreo, Jublia |
| Incyte Corporation | $241.33 | 2024-2025 | Opzelura |
| Genzyme Corporation | $239.70 | 2024-2025 | |
| Mylan Specialty L.P. | $165.65 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $150.08 | 2024-2025 | |
| Revance Therapeutics, INC. | $140.11 | 2025 | Daxxify |
| Janssen Scientific Affairs, LLC | $123.83 | 2024 | Tremfya |
| Galderma Laboratories, L.P. | $121.08 | 2023 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.08 | 2024-2025 | |
| Organon LLC | $65.44 | 2024 | |
| Leo Pharma INC. | $62.51 | 2025 | Adbry, Anzupgo |
| Merz North America, INC. | $57.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.60 | 2024 | Sotyktu |
| Amgen INC. | $45.12 | 2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $44.21 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $20.37 | 2024 | Trelegy Ellipta |
| Grifols USA, LLC | $19.36 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.70 | 2025 | |
| Biofrontera INC. | $11.29 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.